Sanofi (SNY) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Sanofi's earnings call reflects strong financial performance, particularly with 9.7% sales growth and successful new product launches like Dupixent and Beyfortus. The company maintains a stable tax rate and is executing a significant share buyback program. While there are concerns about R&D expenses and margin growth, the optimistic guidance for Dupixent and new pipeline developments in immunology are positive indicators. The Q&A section reveals confidence in new acquisitions and market strategies, despite some uncertainties in regulatory outcomes and pricing pressures. Overall, the sentiment leans positive with potential stock price growth.
Key Financial Performance
Net Sales Net sales increased by 10.1% at constant exchange rate in Q2. This growth was primarily driven by Immunology, by our pharma launches and by Beyfortus.
Gross Margin Gross margin improved by 1.5 percentage points, largely led by an improved product mix and efficiencies.
R&D Expenses R&D expenses increased by 17.7% due to the lower base of comparison last year with the onetime reimbursement from Sobi. Underlying R&D expenses, excluding this reimbursement, increased by around 7%.
Business EPS Business EPS was EUR 1.59, up 8.3%, reflecting our strong sales performance and improved gross margin.
Dupixent Sales Dupixent sales reached EUR 3.8 billion, up 21% in Q2, driven by the continued strong demand and improved indications across geographies. Momentum has been driven by the market growth across all indications where biopenetration remains low as well as by recent launches, including COPD.
U.S. Dupixent Sales In the U.S., sales reached EUR 2.8 billion, up 22.7% as Dupixent continues to lead in both new-to-brand prescriptions and total prescriptions across all established indications.
Outside U.S. Dupixent Sales Outside the U.S., sales again exceeded the EUR 1 billion mark, driven by volume growth in key markets.
Vaccine Business Sales Our vaccine business delivered solid growth in Q2, with sales increasing by 10.3%, driven by the Beyfortus expansion and benefiting from the effect of a late 2024-2025 flu season in the Northern Hemisphere.
Ayvakit Sales Ayvakit reached USD 175 million in sales in Q2. While this performance is not included in the Sanofi Q2 financials, it underscores both the high unmet need and Ayvakit's potential as the first approved medicine in advanced and indolent systemic mastocytosis.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ALTUVIIIO: Extended its strong performance, increasing market share through patient switches.
Beyfortus: Expanded presence in Southern Hemisphere countries, though these are smaller markets compared to Northern Hemisphere.
Qfitlia: Following FDA approval at the end of Q1, recorded initial sales with expected uptake.
Dupixent: Sales reached EUR 3.8 billion, up 21% in Q2, driven by strong demand and improved indications across geographies. Recent launches include COPD and CSU.
Ayvakit: Achieved USD 175 million in sales in Q2, marking strong performance in systemic mastocytosis.
Vaccines: Solid growth in Q2 with sales increasing by 10.3%, driven by Beyfortus expansion and late flu season in Northern Hemisphere.
Vicebio acquisition: Entered agreement to acquire Vicebio, enhancing vaccine development for respiratory pathogens.
Gross margin: Improved by 1.5 percentage points due to better product mix and efficiencies.
R&D expenses: Increased by 17.7%, reflecting investments in pipeline and acquisitions.
Capital redeployment: Executed acquisitions of Dren Bio, Vigil Neuroscience, Blueprint, and Vicebio, aligning with strategic priorities.
Sustainability: Ranked as the world's 10th most sustainable company by TIME, with eco-design principles for medicines and vaccines.
Pipeline expansion: Acquired assets like Ayvakit and VG-3927, focusing on rare diseases and immunology.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Potential U.S. tariffs on EU exports could create uncertainties and negatively impact financial performance.
Competitive Pressures: Flu vaccine sales are expected to decrease by a mid-teens percentage due to competitive forces, particularly in the U.S. and Germany.
Regulatory Hurdles: Regulatory decisions are pending for several key drugs, including rilzabrutinib for ITP and other rare diseases, which could impact timelines and market entry.
Supply Chain and Operational Risks: Seasonality of flu and RSV vaccines creates uneven revenue distribution, with a larger portion of sales expected in the second half of the year.
Economic Uncertainties: Foreign exchange impact is estimated to negatively affect sales by 4% and EPS by 6% for the full year 2025.
Strategic Execution Risks: The integration of recent acquisitions like Blueprint Medicines and Vicebio poses challenges in aligning operations and achieving expected financial returns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Sales Growth: Sanofi has refined its 2025 sales guidance to high single-digit percentage sales growth at constant exchange rates, driven by strong performance in new launches, vaccines, and Dupixent.
Dupixent Sales Projections: Sanofi aims to achieve approximately EUR 22 billion in Dupixent sales by 2030, supported by market growth, expanded indications, and recent launches.
Vaccine Business Outlook: Sanofi anticipates modest growth for Beyfortus in 2025 and expects flu vaccine sales to decrease by a mid-teens percentage due to competitive forces. The sales split is projected to be 75% in Q3 and 25% in Q4.
R&D Expenses: Sanofi expects a moderate increase in R&D expenses in H2 2025, with a focus on supporting growth and future launches.
EPS Guidance: Sanofi confirms its EPS guidance of low double-digit percentage growth at constant exchange rates for 2025, absorbing additional costs from newly acquired businesses.
Regeneron Development Balance Impact: Sanofi projects a negative year-on-year BOI impact of approximately EUR 300 million in 2026 and EUR 800 million in 2027 due to the reimbursement arrangement with Regeneron.
Amvuttra Royalties: Sanofi expects significant royalty revenue from Amvuttra, contributing to its financial outlook until the end of the decade.
Pipeline Developments: Sanofi plans to advance its pipeline with new acquisitions and regulatory submissions, including rilzabrutinib for ITP and other rare diseases, and efdoralprin alfa for alpha-1 antitrypsin deficiency.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: We are executing our EUR 5 billion share buyback program in 2025, with over 80% already completed as of today. We remain firmly committed to completing the full program by the end of this year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the current status of Sanofi's R&D transformation and pipeline progress?
A:Sanofi is undergoing an R&D transformation, which is a long-term process expected to take 5-7 years. The company remains committed to its 12 blockbuster assets, including amlitelimab, frexa, and balinatunfib. Amlitelimab is expected to have its first Phase III readout soon. Management is optimistic about the progress but acknowledges that not all assets will succeed.
Q:How is Sanofi managing its SG&A and R&D expenses, and what is the outlook for margins in 2026?
A:Sanofi reported a 17% increase in R&D expenses in the quarter, with an underlying increase of 7% after excluding exceptional items. SG&A expenses have also increased but at a rate half of the sales growth. Management expects tight cost control and growth leverage to drive BOI (Business Operating Income) growth in absolute terms in 2026, but they did not commit to margin growth as a percentage of sales.
Q:What is the performance and outlook for Dupixent, particularly in China and new indications like COPD?
A:Dupixent continues to show strong growth, with over 30% volume growth in China despite pricing pressures. The product is also seeing positive adoption in new indications like COPD, with strong growth in pulmonologists' offices. Management remains optimistic about Dupixent's diversified growth across geographies and indications.
Q:What is the status of amlitelimab and its potential in atopic dermatitis (AD)?
A:Amlitelimab is being evaluated in the OCEANA program, with a focus on Q4W (every four weeks) dosing. The STREAM-AD study showed promising results, with over 60% of patients maintaining their response at 24 weeks off-drug. Management believes that a longer interval of treatment coupled with efficacy comparable to the standard of care would be highly valued in the market.
Q:What are the financial implications of the Blueprint acquisition and its competitive positioning?
A:The Blueprint acquisition aligns with Sanofi's focus on immunology and rare diseases. Management is confident in Ayvakit's competitive positioning, even with new entrants like bezuclastinib. The EUR 2 billion peak sales guidance for Ayvakit factors in competition and market growth.
Q:What is the outlook for Sanofi's flu vaccine business in 2025?
A:Sanofi expects a mid-teens percentage decline in flu vaccine sales in 2025 due to competitive pricing pressures, particularly in the U.S. and Germany. However, the company remains a leader in the flu market and is optimistic about the long-term potential of flu-COVID-19 combination vaccines.
Q:What is the status of tolebrutinib in SPMS and PPMS, and what are the expectations for its safety profile?
A:Tolebrutinib is in active regulatory discussions for SPMS, with results for PPMS expected later in the year. Management anticipates a safety profile for PPMS consistent with SPMS, including liver toxicity data.
Q:What is Sanofi's approach to M&A and future acquisitions?
A:Sanofi plans to focus on early-phase assets in the EUR 2 billion to EUR 5 billion range, aligning with its strategy to strengthen its pipeline in areas where it already has expertise. The company aims to maintain its AA credit rating while pursuing these opportunities.
Q:What is the outlook for Beyfortus in the RSV prevention market?
A:Beyfortus is expected to grow in 2025 due to market expansion and its strong data set. Despite new competition, Sanofi believes Beyfortus will remain the dominant player in the RSV prevention market.
Q:What is the status of itepekimab in COPD?
A:Itepekimab showed mixed results in its AERIFY-1 and AERIFY-2 studies. Sanofi is working with Regeneron to understand the differences in outcomes and will consult with regulators for next steps.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on 2026 margins as a percentage of sales, citing uncertainties such as the end of Regeneron R&D reimbursement and potential divestment income. Additionally, they did not provide detailed comments on the potential impact of U.S. pricing reforms or the EU-U.S. trade deal on their business.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ayvakit
BOI
Beyfortus
Blueprint
Co
DR
Dupixent
EUR sale
Executive VP
François
LLC Research
Northern Hemisphere
RD
Regeneron
Research Division
Securities
acquisition
capital
development balance
digit percentage
eco
exchange rate
flu
immunology
indication
launch
margin
market
medicine vaccine
payment
reimbursement
royalty
sale EUR
share
SNY Transcript
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Neutral9-23
Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-9
Sanofi (SNY) Q2 2025 Earnings Call Transcript
Positive7-31
Sanofi's earnings call reflects strong financial performance, particularly with 9.7% sales growth and successful new product launches like Dupixent and Beyfortus. The company maintains a stable tax rate and is executing a significant share buyback program. While there are concerns about R&D expenses and margin growth, the optimistic guidance for Dupixent and new pipeline developments in immunology are positive indicators. The Q&A section reveals confidence in new acquisitions and market strategies, despite some uncertainties in regulatory outcomes and pricing pressures. Overall, the sentiment leans positive with potential stock price growth.
Sanofi (SNY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Neutral6-10
SNY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
